Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Pasoon HellamandMarleen G H van de SandeMichael T NurmohamedRonald F Van VollenhovenRosemary J HollickOvidiu RotariuŽiga RotarKatja Perdan PirkmajerDan NordströmAnna-Mari HokkanenBrigitte MichelsenTore K KvienBente GlintborgMerete Lund HetlandMikkel ØstergaardAnne Gitte LoftKarel PavelkaJakub ZávadaIsabel CastrejonLucia Otero VarelaBjorn GudbjornssonOlafur PalssonTor OlofssonJohan Karlsson WallmanAdrian CiureaMichael John NissenTuba D YildirimFatoş ÖnenCatalin CodreanuCorina MogosanMaria Jose SantosElsa Viera SousaFlorenzo IannoneBruno FredianiLykke Midtbøll ØrnbjergJos W R TwiskIrene E van der Horst-BruinsmaPublished in: Rheumatology (Oxford, England) (2024)
In axSpA patients initiating their first TNFi, baseline sex differences in BASDAI and BASFI increased two-fold after 6 months of treatment and persisted thereafter, with worse scores in women. Several baseline characteristics moderated the sex differences, though none could fully account for them. These findings improve our understanding of sex differences and underscore their importance in axSpA.